Catalyst Wire Dossier Catalyst Wire Dossier

BI 660848

· Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 660848, covering 2013-11-01 to 2013-11-01. Get the full timeline:

Most recent: Clinical Trial Update: To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle). [Phase 1]

See pricing